Evidence map›Paper›PMID 24634783›Full record

ArticleJournal of skin cancer2014

Gene expression differences predict treatment outcome of merkel cell carcinoma patients.

Loren Masterson, Bryan J Thibodeau, Laura E Fortier, Timothy J Geddes, Barbara L Pruetz, Rajwant Malhotra, Richard Keidan, George D Wilson

Open access · goldAbstract read
In one paragraph

Article in Journal of skin cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Loren MastersonDepartment of General Surgery, Beaumont Health System, Royal Oak, MI 48073, USA.
Bryan J ThibodeauDepartment of Beaumont BioBank, Beaumont Health System, 3811 West 13 Mile Road 105-RI, Royal Oak, MI 48073, USA.
Laura E FortierDepartment of Beaumont BioBank, Beaumont Health System, 3811 West 13 Mile Road 105-RI, Royal Oak, MI 48073, USA.
Timothy J GeddesDepartment of Beaumont BioBank, Beaumont Health System, 3811 West 13 Mile Road 105-RI, Royal Oak, MI 48073, USA.
Barbara L PruetzDepartment of Beaumont BioBank, Beaumont Health System, 3811 West 13 Mile Road 105-RI, Royal Oak, MI 48073, USA.
Rajwant MalhotraDepartment of Anatomic Pathology, Beaumont Health System, Royal Oak, MI 48073, USA.
Richard KeidanDepartment of General Surgery, Beaumont Health System, Royal Oak, MI 48073, USA.
George D WilsonDepartment of Beaumont BioBank, Beaumont Health System, 3811 West 13 Mile Road 105-RI, Royal Oak, MI 48073, USA.
Beaumont Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the rarity of Merkel cell carcinoma (MCC), prospective clinical trials have not been practical. This study aimed to identify biomarkers with prognostic significance. While sixty-two patients were identified who were treated for MCC at our institution, only seventeen patients had adequate formalin-fixed paraffin-embedded archival tissue and followup to be included in the study. Patients were stratified into good, moderate, or poor prognosis. Laser capture microdissection was used to isolate tumor cells for subsequent RNA isolation and gene expression analysis with Affymetrix GeneChip Human Exon 1.0 ST arrays. Among the 191 genes demonstrating significant differential expression between prognostic groups, keratin 20 and neurofilament protein have previously been identified in studies of MCC and were significantly upregulated in tumors from patients with a poor prognosis. Immunohistochemistry further established that keratin 20 was overexpressed in the poor prognosis tumors. In addition, novel genes of interest such as phospholipase A2 group X, kinesin family member 3A, tumor protein D52, mucin 1, and KIT were upregulated in specimens from patients with poor prognosis. Our pilot study identified several gene expression differences which could be used in the future as prognostic biomarkers in MCC patients.

Identifiers

PMID24634783
PMCPMC3929072
OpenAlexW2122049229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.